There are 2789 resources available
1192MO - Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: Analysis from the CHRYSALIS study
Presenter: Natasha B. Leighl
Session: Mini oral session - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
1193MO - Amivantamab plus lazertinib in post-osimertinib, post-platinum chemotherapy EGFR-mutant non-small cell lung cancer (NSCLC): Preliminary results from CHRYSALIS-2
Presenter: Catherine A. Shu
Session: Mini oral session - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
LBA50 - A randomized phase III study comparing cisplatin-pemetrexed (cis-pem) with carboplatin (C)-paclitaxel (P)-bevacizumab (B) in chemotherapy naïve patients (pts) with advanced KRAS mutated non-small cell lung cancer (NSCLC): NVALT22
Presenter: Anne-Marie Dingemans
Session: Mini oral session - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
LBA51 - EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC)
Presenter: Miranda Gogishvili
Session: Mini oral session - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
1194MO - Canakinumab (CAN) + docetaxel (DTX) for the second- or third-line (2/3L) treatment of advanced non-small cell lung cancer (NSCLC): CANOPY-2 phase III results
Presenter: Luis Paz-Ares
Session: Mini oral session - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
576MO - Health-related quality of life (HRQoL), pain and safety outcomes in the phase III VISION study of <sup>177</sup>Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
Presenter: Karim Fizazi
Session: Mini oral session - Genitourinary tumours, prostate
Resources:
Abstract
Slides
Webcast
LBA26 - Darolutamide maintenance in metastatic castration resistant prostate cancer (mCRPC) previously treated with novel hormonal agents (NHA) and non-progressive disease after subsequent treatment with a taxane: A randomized double-blind placebo-controlled phase II trial (SAKK 08/16)
Presenter: Richard Cathomas
Session: Mini oral session - Genitourinary tumours, prostate
Resources:
Abstract
Slides
Webcast
578MO - Phase Ib/II study of sabizabulin (VERU-111), an androgen receptor transport disruptor, in men with metastatic castration resistant prostate cancer (mCRPC) who failed an androgen receptor targeting agent (ARTA)
Presenter: Mark Markowski
Session: Mini oral session - Genitourinary tumours, prostate
Resources:
Abstract
Slides
Webcast
828MO - Exonic mutation profile of primary gastrointestinal diffuse large B-cell lymphoma
Presenter: Shan-Shan Li
Session: Mini oral session - Haematological malignancies
Resources:
Abstract
Slides
Webcast
830MO - Integrated driver mutations profile of Chinese NK/T cell lymphoma
Presenter: Ting-zhi Liu
Session: Mini oral session - Haematological malignancies
Resources:
Abstract
Slides
Webcast